[go: up one dir, main page]

WO1995032735A3 - Inversion des deviations constatees dans le repertoire des lymphocytes, pour prevenir ou soigner une maladie - Google Patents

Inversion des deviations constatees dans le repertoire des lymphocytes, pour prevenir ou soigner une maladie Download PDF

Info

Publication number
WO1995032735A3
WO1995032735A3 PCT/CA1995/000319 CA9500319W WO9532735A3 WO 1995032735 A3 WO1995032735 A3 WO 1995032735A3 CA 9500319 W CA9500319 W CA 9500319W WO 9532735 A3 WO9532735 A3 WO 9532735A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
infection
infected
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1995/000319
Other languages
English (en)
Other versions
WO1995032735A2 (fr
Inventor
Geoffrey W Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Network Research Ltd
Original Assignee
Immune Network Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Network Research Ltd filed Critical Immune Network Research Ltd
Priority to AU25203/95A priority Critical patent/AU2520395A/en
Publication of WO1995032735A2 publication Critical patent/WO1995032735A2/fr
Publication of WO1995032735A3 publication Critical patent/WO1995032735A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes pour diminuer le nombre de cellules infectées par le VIH ou de cellules sensibles à l'infection par le VIH chez un hôte. En pratique, cela se fait en exposant les cellules à un élément sélectif par rapport à une région V (ESRV) qui se fixe aux récepteurs des lymphocytes T (RCT) d'une famille définie de régions V (FDRV) qui est infectée d'une manière préférentielle par le VIH. L'ESRV à effet thérapeutique peut être un anticorps qui se fixe aux RCT d'une FDRV et il est capable de provoquer une cytotoxicité chez des cellules infectées et des cellules sensibles à l'infection, soit seul, soit en association avec des facteurs hôtes, soit encore fusionné avec une toxine. On peut diminuer le nombre de cellules sensibles à une infection par le VIH à des fins préventives ou dans certains cas thérapeutiques, par une immunisation avec un anticorps ou des récepteurs de lymphocytes T, laquelle induit une réponse immunitaire aboutissant à des anticorps qui se fixent aux RCT d'une FDRV associée à l'infection par le VIH. Ces anticorps diminuent la viabilité des cellules infectées ou sensibles à l'infection. On décrit également des moyens pour diagnostiquer et traiter des maladies dans lesquelles il y a une distorsion du répertoire immunitaire, y compris dans les cas où il y a peu d'informations sur l'agent pathogène ou les mécanismes de la pathogenèse. On réalise ceci en sélectionnant les anticorps monoclonaux permettant de détecter les changements du répertoire des anticorps caractéristiques d'une maladie, ce qui permet de faire un diagnostic et d'influer sur le répertoire du système immunitaire de façon contraire à la déviation caractéristique de la maladie ou de l'affection, pour la prévenir ou la traiter.
PCT/CA1995/000319 1994-05-31 1995-05-31 Inversion des deviations constatees dans le repertoire des lymphocytes, pour prevenir ou soigner une maladie Ceased WO1995032735A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25203/95A AU2520395A (en) 1994-05-31 1995-05-31 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25170794A 1994-05-31 1994-05-31
US08/251,707 1994-05-31

Publications (2)

Publication Number Publication Date
WO1995032735A2 WO1995032735A2 (fr) 1995-12-07
WO1995032735A3 true WO1995032735A3 (fr) 1996-02-29

Family

ID=22953068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000319 Ceased WO1995032735A2 (fr) 1994-05-31 1995-05-31 Inversion des deviations constatees dans le repertoire des lymphocytes, pour prevenir ou soigner une maladie

Country Status (2)

Country Link
AU (1) AU2520395A (fr)
WO (1) WO1995032735A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050240353A1 (en) * 2004-04-21 2005-10-27 Hoffmann Technologies Corporation Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008491A1 (fr) * 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugues d'anticorps anti-idiotype et de porteurs ainsi que leur emploi en immunisation par epitope
EP0503916A1 (fr) * 1991-03-11 1992-09-16 Idec Pharmaceuticals Corporation Méthodes pour prélever des réactifs d'anticorps; anticorps d'anti-idiotype; et formulations de vaccin de sida
WO1993017694A1 (fr) * 1992-03-09 1993-09-16 San Diego Regional Cancer Center Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008491A1 (fr) * 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugues d'anticorps anti-idiotype et de porteurs ainsi que leur emploi en immunisation par epitope
EP0503916A1 (fr) * 1991-03-11 1992-09-16 Idec Pharmaceuticals Corporation Méthodes pour prélever des réactifs d'anticorps; anticorps d'anti-idiotype; et formulations de vaccin de sida
WO1993017694A1 (fr) * 1992-03-09 1993-09-16 San Diego Regional Cancer Center Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C. SUSAL ET AL.: "Complementarities and network interactions in AIDS.", JOURNAL OF AUTOIMMUNITY, vol. 6, no. 5, pages 601 - 610 *
G. HOFFMANN ET AL.: "An idiotypic network model of AIDS immunopathogenesis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, no. 8, 15 April 1991 (1991-04-15), WASHINGTON, DC, USA, pages 3060 - 3064 *
G. HOFFMANN: "An idiotypic network model of AIDS pathogenesis that is based on coselection (mutual positive selection) of HIV and helper T cells will be reviewed.", ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, vol. 41 supplement, 6 April 1994 (1994-04-06) - 8 April 1994 (1994-04-08), BUDAPEST, HUNGARY, pages 57 *
G. HOFFMANN: "Co-selection in immune network theory and in AIDS pathogenesis.", IMMUNOLOGY AND CELL BIOLOGY, vol. 72, no. 4, ADELAIDE, AUSTRALIA, pages 338 - 346 *
G. HOFFMANN: "On a role for co-selection between helper T cells and HIV in AIDS pathogenesis.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 8 part 2, 15 April 1993 (1993-04-15), BALTIMORE, MD, USA, pages 102A *
G. HOFFMANN: "The T cell receptor and AIDS pathogenesis.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 41, no. 4, OXFORD, GB, pages 331 - 337 *
H. WANG ET AL.: "Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 22, no. 7, WEINHEIM, GERMANY, pages 1749 - 1755 *
N. REBAI ET AL.: "Analysis of the T-cell receptor beta-chain variable region (Vbeta) repertoire in monozygotic twins discordant for human immunodeficiency virus: Evidence for perturbations of specific Vbeta segments in CD4+ T cells of the virus-positive twins.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, no. 4, 15 February 1994 (1994-02-15), WASHINGTON, DC, USA, pages 1529 - 1533 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date
WO1995032735A2 (fr) 1995-12-07
AU2520395A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
Van der Zee et al. Inhibition of complement activation by IgG4 antibodies
Santoro et al. Serodiagnosis of Toxoplasma infection using a purified parasite protein (P30)
Corbeil et al. Adherence of Tritrichomonas foetus to bovine vaginal epithelial cells
Lehner et al. Association between HLA-DR antigens and helper cell activity in the control of dental caries
Griffiths et al. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum
Ekerfelt et al. Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: secretion of IFN-γ predominates over IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes
KR890014130A (ko) 포유동물 내에서 b-임파구의 억제 및 면역 억제 배합물.
EP0867189A3 (fr) Anticorps monoclonaux réagissant avec des régions déterminées du récepteur de l'antigène de cellules
BR0013201A (pt) Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado
Baughn et al. Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis.
Ey et al. Complement-fixing IgG1 constitutes a new subclass of mouse IgG
SE9401460D0 (sv) Antigen/antibody specificity exhanger
FI950002L (fi) Anti-HCV-vasta-aineiden immunomääritykset käyttäen antigeenejä joissa on konformaatioepitooppeja
AU1157100A (en) Detection of acid-resistant micro-organisms in a stool
Chye et al. Immunodiagnosis of human eosinophilic meningitis using an antigen of Angiostrongylus cantonensis L5 with molecular weight 204 kD
Parr et al. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus
ATE146528T1 (de) Kleinzelliger lungenkarzinom-spezifischer antikörper und antigenen
Lehmann et al. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea
US5626844A (en) Monoclonal antibody against ricin A chain
WO1995032735A3 (fr) Inversion des deviations constatees dans le repertoire des lymphocytes, pour prevenir ou soigner une maladie
Al-Harbi et al. Production and characterization of monoclonal antibodies against tilapia Oreochromis niloticus immunoglobulin
Möller et al. Mitogenic properties of rabbit anti‐human β2‐microglobulin for murine B cells
Iwai et al. Immunoglobulin classes of anti‐Sendai virus antibody detected by ELISA in infected nude mouse serum
Ainbender et al. Radioautographic studies of poliovirus binding by human immunoglobulins.
Bahr et al. Antibody levels and in vitro lymphoproliferative responses to Streptococcus pyogenes erythrogenic toxin A and mitogen of patients with rheumatic fever

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA